InMode Ltd. (NASDAQ:INMD) Shares Sold by Corebridge Financial Inc.

Corebridge Financial Inc. decreased its position in InMode Ltd. (NASDAQ:INMD) by 15.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 35,774 shares of the healthcare company’s stock after selling 6,742 shares during the quarter. Corebridge Financial Inc. owned about 0.05% of InMode worth $597,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in INMD. Quarry LP lifted its stake in shares of InMode by 154.3% during the third quarter. Quarry LP now owns 3,781 shares of the healthcare company’s stock valued at $64,000 after buying an additional 2,294 shares during the period. SBI Securities Co. Ltd. acquired a new position in InMode in the fourth quarter valued at $87,000. Farther Finance Advisors LLC boosted its stake in InMode by 26.2% in the 4th quarter. Farther Finance Advisors LLC now owns 5,555 shares of the healthcare company’s stock worth $93,000 after buying an additional 1,154 shares during the last quarter. National Bank of Canada FI grew its holdings in InMode by 6.2% in the 3rd quarter. National Bank of Canada FI now owns 9,985 shares of the healthcare company’s stock valued at $169,000 after buying an additional 579 shares during the period. Finally, HighTower Advisors LLC acquired a new position in shares of InMode during the 4th quarter valued at about $180,000. 68.04% of the stock is currently owned by hedge funds and other institutional investors.

InMode Stock Performance

NASDAQ INMD opened at $15.40 on Tuesday. The firm has a market capitalization of $1.07 billion, a price-to-earnings ratio of 6.55 and a beta of 1.96. InMode Ltd. has a one year low of $14.56 and a one year high of $19.99. The company’s 50 day moving average price is $18.29 and its 200 day moving average price is $17.77.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. Needham & Company LLC restated a “hold” rating on shares of InMode in a report on Tuesday, February 4th. Barclays boosted their price objective on shares of InMode from $26.00 to $29.00 and gave the company an “overweight” rating in a research note on Wednesday, February 5th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat, InMode presently has a consensus rating of “Hold” and a consensus target price of $22.25.

About InMode

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.